{"id":"b1a6693569bb","type":"article","url":"https://hartvaat.nl/2026/02/05/efimosfermine-alfa-bij-mash-met-f2-f3-fibrose-fase-2-resultaten/","title":"Efimosfermine alfa bij MASH met F2/F3-fibrose: fase 2-resultaten","title_en":"Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial","category":"algemeen","category_label":"Algemeen","professions":["apotheker","internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02276-7/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02276-7/fulltext","authors":["Mazen Noureddin","Kris V Kowdley","Tatjana Odrljin","Gerard Bain","Jeff Zhao","Brenda Jeglinski","Margaret James Koziel","Rohit Loomba"],"significance":8,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":[],"congress":"","summary_en":"This phase 2 trial of efimosfermin alfa (FGF21 analogue) showed favorable tolerability in patients with MASH and F2/F3 fibrosis. The results support further development of metabolic therapies targeting the liver-cardiovascular axis.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In deze fase 2-trial werd eenmaal per maand efimosfermine goed verdragen bij deelnemers met biopsie-bevestigde MASH en F2/F3-fibrose. De resultaten ondersteunen verdere ontwikkeling van efimosfermine voor MASH-gerelateerde leverziekte.","abstract_original":"In this phase 2 trial, treatment with efimosfermin once per month was generally well tolerated in participants with biopsy-confirmed MASH and F2 or F3 fibrosis. These results support the further development of efimosfermin for treatment of MASH-related fibrosis."}